Clinical Trial Update: Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma [Phase 3]

View source ↗

Summary

Open-label extension study assessing the long-term safety and efficacy of reslizumab (3.0 mg/kg) in eosinophilic asthma patients aged 12-75; the study is termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Asthma

Drugs mentioned

• reslizumab (reslizumab)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Eosinophilic Asthma | Phase 3 | Status: TERMINATED | Results posted: 2016-06-06